Epidemiological data from Europe, the USA and elsewhere in the developed world show a steep decline in co ronary heart disease (CHD) mortality during the last 40 years 1 . Concern about levelling of mortality rates in younger adults 2 has been somewhat alleviated by data from Th e Netherlands showing that in men aged <55 years, rates of decline have again accelerated, increasing from only 16% in 1993-1999 to 46% in 1999-2007 3 . A similar pattern was observed in young women with ra tes of decline of 5% and 38% during the same time pe riods. Th is is encouraging, particularly in the context of data from Denmark and the UK showing declining mortality and also a sharp fall in standardized incidence rates for acute myocardial infarction indicating that coronary prevention, as well as acute treatments, has contributed to recent mortality trends 4, 5 . Meanwhile an Australian study reminds us that myocardial infarction is but one of several manifestations of cardiovascular disease by reporting that decreasing incidence and recurrence rates for hospitalized CHD from 2000 to 2007 have also been seen for cerebrovascular and peripheral arterial disease 6 . However, the epidemiological news is not all good, and data from the UK show that the pernicious relationship between socioeconomic status (SES) and CHD has shown no tendency to go away in recent years, the gradients between top and bottom SES quintile groups for hospital admissions remaining essentially unchanged across the age range 7 . Whether this has contributed to the almost 3-fold risk of myocardial infarction associated with stillbirth and 9-fold risk associated with recurrent miscarriage in a recent German study is unclear because the investigators made no adjustment for SES 8 . Nor is it clear if SES has contributed to the persistent ethnic diff erences in both US and UK studies of CHD mortality although other factors appear also to be im portant. Th us, African-American men have greater exposure to CHD risk factors than Caucasians and, when adjustment is made for this, their susceptibility to CHD is no greater, although mortality rates are twice as high 9 . For African-American women, incidence and mortality rates are higher than their Caucasian counterparts. Th ese findings suggesting that exposure to risk factors contributes to ethnic diff erences in the inci dence of CHD are to some extent reflected in a re cent report from the Health Survey for England in which 13 293 Caucasian and 2120 S Asians consented to mortality follow-up 10 . Physical inactivity was more frequent in S Asians compared with Caucasians (47% vs 28%) and explained >20% of their excess CHD mor tality. Certainly, the emerging consensus is that the excess CHD mortality among UK S Asians is driven almost entirely by their increased susceptibility to disease and not by increased case-fatality rates 11 .
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DIAGNOSIS OF STABLE CORONARY ARTERY DISEASE
Th e recent AHA/ACC guideline update 12 emphasized the importance of individualizing the diagnostic workup based on the estimated probability of coronary artery disease. In this respect, it mirrored an earlier National Institute of Clinical Excellence (NICE) guideline on chest pain diagnosis 13 , but there were important diff erences in the recommendations for non-invasive testing, the new AHA/ ACC guideline preferring the exercise ECG as the initial diagnostic approach for most patients, (NICE had previously counselled against use of the exercise ECG based on its relatively poor diagnostic performance) with pharmacologic radionuclide, cardiac MRI or stress echocardiography testing in reserve for patients unable to exercise. Recommendations for cardiac CT coronary angiography (CTCA) were cautious, and invasive angiography was recommended for diagnostic purposes only if the results of non-invasive testing suggested a high likelihood of severe 3-vessel or left main coronary artery disease, and the patient was willing to undergo revascularizations. In general, therefore, the AHA/ACC guideline update was less prescriptive than the earlier NICE guideline, perhaps partly because it put less emphasis on the cost eff ectiveness of its recommendations.
MANAGEMENT OF STABLE CORONARY ARTERY DISEASE
Th e recent NICE guideline14 recommended initial treatment with a short-acting nitrate and a β-blocker and/or a calcium channel blocker for control of angina plus aspirin and a statin for secondary prevention. Lifestyle measures were also emphasized. For patients with continuing symptoms cardiac catheterization with a view to revascularization was recommended, additional antianginal treatment (long-acting nitrates or one of the newer agents) only being indicated for patients unsuitable for revascularization. It was further recommended that the mode of revascularization (percutaneous coronary intervention (PCI) versus coronary artery bypass graft ing (CABG)) should best be determined by a multidisciplinary group, a recommendation that has also been emphasized by European guideline groups 15 , bearing in mind the potential for prognostic benefit from CABG in patients with complex multivessel and left main stem disease 16 , particularly those with diabetes. For patients with symptoms adequately controlled with medical treatment, the guideline recommended discussion of the potential for prognostic improvement with CABG. Th ose patients prepared to proceed to CABG might then be off ered diagnostic cardiac catheterization to rule out complex multivessel and left main stem disease, which a recent meta-analysis reported in as many as 36% (18.5-48 .8%) of cases of stable coronary disease selected for cardiac catheterization 17 .
SECONDARY PREVENTION OF STABLE CORONARY DISEASE
Th e scope for improving secondary prevention in patients with stable coronary artery disease has been emphasized in two recent reports. In Th e multinational REduction of Atherothrombosis for Continued Health (REACH) Registry, 20 588 symptomatic patients were analyzed for 'good control' of cardiovascular risk factors, defined as three to five of systolic blood pressure <140 mm Hg, diastolic blood pressure <90 mm Hg, fasting glycaemia <110 mg/dL, total cholesterol <200 mg/dL, non-smoking 18 . Only 59.4% had good control of risk factors at baseline, but this was associated with lower mortality (OR 0.89; 95% CI 0.79 to 0.99) at 36 months, compared with poor control. In the UK ASPIRE-2-PREVENT survey, 676 patients with CHD (25.6% women) had the following rates of major risk factors: smoking 14.1%, obesity 38%, physical inactivity 83.3%, blood pressure ≥130/80 mmHg, total cholesterol ≥4 mmol/L and diabetes 17.8%, leading the authors to conclude that there is considerable potential for reducing cardiovascular risk in these patients and thereby improve prognosis 19 . Clopidogrel. Th e availability of low-cost generic clopidogrel prompted a NICE review of its cost eff ectiveness which recommended it should now supersede aspirin in certain high-risk groups, namely patients with multivascular disease, peripheral vascular disease and myocardial infarction 20 . However, clopidogrel is metabolized by enzymes in the hepatic cytochrome P450 (CYP) system, and variability in its antiplatelet activity may occur because the activity of these enzymes is influenced by common genetic variations, and also by a number of commonly used drugs. Several studies have reported loss-of-function alleles in CYP2C 19 that result in reduced activation of clopidogrel 21 and a modest lowering of antiplatelet activity 22 which have been associated with an increased risk of cardiovascular events in some meta-analyses 23 . Conversely, gain-offunction alleles have been associated with reduced cardiovascular risk among clopidogrel-treated patients 24 A recent meta-analysis, however, has commented on the tendency of small studies to bias conclusions about the way genetic variants influence clinical outcomes, and in larger studies of clopidogrel therapy with ≥200 outcome events found no eff ect of loss-of-function alleles on cardiovascular risk 25 . At present, therefore, there seems to be no compelling indication for genetic testing to guide clopidogrel treatment although the topic remains a subject of ongoing debate. Also debated is the interaction of clopidogrel with some commonly used drugs, particularly proton pump inhibitors (PPI) and amlodipine. A recent meta-analysis of studies of PPIs in patients treated with clopidogrel found clear evidence of reduced platelet activity but although clinical outcomes appeared adversely aff ected by the interaction, the authors urged cautious interpretation, pointing out the heterogeneity caused by retrospective studies. When analysis was restricted to prospective studies of PPIs and clopidogrel, adverse clinical consequences could no longer be demonstrated (OR 1.13 (0.98 to 1.30)) 26 . Similarly, the clinical impact of amlodipine on responsiveness to clopidogrel remains uncertain. Certainly, there is evidence of interaction, and in one study of 1258 patients receiving clopidogrel, amlodipine administration was associated with higher on treatment platelet reactivity only in those patients with a loss-of-function P450 (CYP) genotype (249±83 vs 228±84 P2Y12 reaction units), and this was associated with a higher incidence of cardiovascular events (4.6% vs 0.6%) 27 . However, in a more recent randomized trial, platelet function in 98 patients with stable coronary artery disease taking clopidogrel was similar regardless of amlodipine therapy 28 . At present, therefore, there is no guideline recommendation about concomitant prescription of these drugs in patients taking clopidogrel, statins, niacin and cholesterol ester transfer protein (CETP) inhibitors. Th e benefits of statins for secondary prevention in patients with stable coronary artery disease are well established. Cardiovascular endpoints are reduced in proportion to the degree of LDL-cholesterol reduction, probably in response to stabilisation and regression of atheromatous plaque. Th e capacity for plaque regression has recently been confirmed by serial IVUS examination in 1039 patients with stable coronary disease randomized to rosuvastatin 40 mg daily or atorvastatin 80 mg daily 29 . Atheroma volume during the 2-year monitoring period decreased by an average of about 1% in both groups, more than previously reported with less intensive statin regimens. However, additional clinical benefits of niacin have now been unequivocally ruled out in the AIM-HIGH trial in which 3414 patients with stable cardiovascular disease taking statins were randomized to receive niacin (n=1718) or placebo (n=1696) 30 . Although niacin significantly increased HDL cholesterol and lowered triglycerides, diff erences in the primary endpoints (a composite of adverse coronary events, strokes and revascularization) were negligible, occurring in 16% of patients in each group. Th e trial was stopped aft er an average follow-up of 3 years when it became clear HDL raising therapy with niacin was clinically ineff ective. All hopes for HDL raising therapy are now invested in CETP inhibitors, and despite safety concerns following the ILLUMINATE trial of torcetrapib 31 , in which treatment was associated with increased mortality despite substantial HDL elevations, other CETP inhibitors are now entering phase III trials. A recent randomized trial of dalcetrapib in patients with acute coronary syndromes was disappointing with no reduction in the risk of recurrent coronary events despite a >30% increase in HDL levels in the treatment group 32 . An efficacy and safety trial of anacetrapib in patients with, or at high risk of, stable coronary disease was favorable, although not powered for clinical outcomes 33 , and evacetrapib has now entered the arena with a recent study showing eff ective HDL raising without the adverse eff ects on blood pressure seen with torcetrapib and, to a lesser extent, dalcetrapib 34 . Whether any of these CETP inhibitors will improve clinical outcomes, however, remains unknown.
Novel lipid-lowering drugs in clinical translation. Conventional lipid-lowering therapies, even when combined with LDL-apherisis, are oft en insufficient to treat to guideline targets patients with familial hypercholesterolaemia (FH), an autosomal dominant disorder of lipid metabolism associated with accelerated coronary disease 35 . Th ere is, therefore, considerable interest in novel therapies currently under investigation, particularly lomitapide, an oral inhibitor of microsomal transfer protein and monoclonal antibodies against PCSK9. A phase II study of lomitapide in homozygous FH showed a 50% reduction in LDL-cholesterol and, although gastrointestinal side eff ects were common, a useful role for the drug seems likely in these homozygous patients 36 . PCSK9 inhibitors have also produced 50-60% reductions in LDL-cholesterol values in clinical studies when added to statins and ezetimibe, but unlike lomitapide, are probably mainly eff ective in heterozygotic FH because they act through interference with LDL receptors which are dysfunctional or completely absent in homozygotes 37, 38 . Th e expectation is that application of these new drugs will allow most patients with FH to achieve target concentrations of LDL cholesterol. An important component of FH management involves identification of other aff ected family members, and cascade screening using genetic testing has been reported as cost eff ective 39 . However, recent evi dence suggests that polygenic disorders account for an appreciable proportion of FH cases 40 , and this will limit the eff ectiveness of cascade screening to relatives of mutation-positive (monogenic) cases. In other patients, with cholesterol levels consistent with an FH genotype, more conventional primary care strategies 41 should remain the screening tool of choice, at least for the time being.
REVASCULARISATION IN STABLE CAD
Percutaneous coronary intervention. Th e COURAGE trial was a game-changer, showing that coronary stenting in patients with stable angina did not improve cardiovascular outcomes compared with optimal medical therapy (OMT) while quality-of-life benefits were short-lived 42, 43 . Now available is a meta-analysis comparing contemporary medical therapy and PCI in eight randomized trials involving 7229 patients with stable CAD 44 . Again, cardiovascular outcomes between the groups were similar during follow-up for an average 4.3 years with no significant clinical benefit for PCI, risks of death (8.9% vs 9.1%) and non-fatal MI (8.9% vs 8.1%) being nearly identical with medical therapy, while diff erences in unplanned revascularization (21.4% vs 30.7%) and persistent angina (29% vs 33%) were small and insignificant. Th e data support recent guideline recommendations for treatment of stable angina (see above), and have been used to challenge those clinicians who continue to off er PCI to patients not receiving OMT 45 . However, FAME-II has now provided some support for an early interventional approach in a randomized comparison of OMT and PCI using drugeluting stents guided by fractional flow reserve (FFR) 46 . Th e study was stopped 17 months earlier than planned because the composite endpoint (all-cause mortality, non-fatal MI, urgent revascularization) occurred in 4.3% of the PCI group compared with 12.7% of the non-PCI (OMT) group. Relief of angina was also more eff ective in the PCI group. Already, PCI guided by FFR has become a recommended strategy in stable coronary artery disease but some feel this is premature 47 . Th us, the treatment diff erence in FAME-II was driven solely by a reduction in urgent revascularization (49 in the OMT alone group; 7 in the FFR-PCI group (HR=0.13, 95% CI 0.06 to 0.30), while the 33 deaths and nonfatal MIs were distributed fairly evenly between the groups. Moreover, the majority of patients undergoing 'urgent' revascularization lacked objective findings of high-risk ischaemia or threshold biomarker elevations, raising concerns of biased selection of patients for invasive ma nagement during follow-up. Nevertheless, the argu ment in favor of interventional management as an initial strategy in stable angina has undoubtedly been strengthened by FAME-II, but final answers to the debate may have to await the findings of the ongoing International Study of Comparative Health Eff ectiveness with Medical and Invasive Approaches (ISCHEMIA Trial; ClinicalTrials.gov number, NCT 01471522), comparing eff ects of revascularization (PCI or CABG) combined with OMT, with OMT alone on cardiovascular death, or MI in patients with stable CAD, and objective evidence of myocardial ischaemia.
Coronary artery bypass surgery. Updated US guidelines 48 have endorsed the NICE recommendation of a multidisciplinary team approach to adjudicating re vascularization decisions in patients with complex co ronary disease, encouraging application of SYNTAX and other scoring systems in arriving at an appropriate decision 49 . Th e potential for CABG compared with PCI to improve prognosis in patients with left main and multivessel CAD is supported by recent cohort studies 50, 51 , and now available are the 5-year follow-up data from SYNTAX in which major adverse cardiac and cerebrovascular events (MACCE) were 26•9% in the CABG group and 37-3% in the PCI group, driven largely by lower rates of non-fatal myocardial infarction and repeat revascularization for CABG, with no significant diff erence in all-cause mortality and stroke compared with PCI 52 . Th e benefits of CABG were particularly evident in patients with intermediate and high SYN-TAX scores, there being no signifi-cant diff erence in outcomes between revascularization strategies for patients with low SYNTAX scores. Any question about the preferred revascularization strategy in patients with diabetes and mutlivessel coronary artery disease has now been answered by the FREEDOM TRIAL which randomized 1900 patients on OMT to either PCI with drug-eluting stents or CABG 53 . Aft er a median followup of 3.8 years, the primary outcome, a composite of death from any cause, non-fatal myocardial infarction, or non-fatal stroke, occurred in 26.6% of the PCI group and 18.7% of the CABG group. Th e authors concluded that CABG is superior to PCI in patients with diabetes and multivessel disease. Th ere is less certainty about the preferred revascularization strategy in left main coronary disease, the SYNTAX investigators reporting similar outcomes for PCI and CABG, a finding consistent with other contemporary studies that identify stenting as a reasonable strategy in appropriately selected cases, even though the need for repeat revascularization is almost invariably higher compared with CABG 54, 55 . Surgical technique has come under considerable scrutiny recently. Concerns about the potential adverse eff ects of endoscopic versus open saphenous vein harvesting have been based largely on a non-randomized cohort study of 1817 patients in whom rates of vein graft failure at 1 year were 47% vs 38%, and rates of death, myocardial infarction or revascularization at 3 years were 20.2% vs 17.4% for endoscopic versus open sa phenous vein harvesting 56 . Th is led NICE to recommend caution in use of the endoscopic technique 57 , but such concerns have now been allayed by the results of two large cohort studies. In the US study of 235 394 Medicare CABG patients in the Society of Th oracic Surgeons (STS), national database mortality rates were similar regardless of harvesting technique, while rates of harvest site complications were lower for the endoscopic technique 58 . A UK study of 4702 CABG patients reported similar findings with no diff erences in inhospital mortality (0.9% vs 1.1%, p=0.71) or midterm mortality (HR 1.04; 95% CI 0.65 to 1.66) for endoscopic versus open vein harvesting 59 . Also under scrutiny have been the relative benefits of off -pump and on-pump CABG. Each has its proponents 60, 61 , but the results of randomized outcome trials have failed to show any clear advantage for off -pump CABG, the 3-year results of the Best Bypass Surgery Trial showing no significant diff erence in the primary com posite outcome of MACCE compared with onpump CABG, but a tendency towards higher mortality 62 . Th is may reflect, at least in part, diff erences in graft patency rates favoring on-pump procedures, the ROO-BY trial reporting rates of 91.4% vs 85.8% for arterial graft s and 80.4% vs 72.7% for saphenous vein graft s in on-pump compared with off -pump patients 63 . Particularly disappointing has been the failure of off -pump surgery to reduce cerebral injury, but a randomized comparison of minimal (MECC) versus conventional (CECC) extracorporeal circulation in 64 patients undergoing CABG has been more promising 64 . MECC was associated with improved cerebral oxygen delivery during surgery, and neurocognitive performance at 3 months was better when compared with CECC.
REMOTE ISCHAEMIC PRECONDITIONING FOR TREATMENT OF STABLE CORONARY DISEASE
Its proponents see remote ischaemic preconditioning (RIPC) as a useful and inexpensive means of improving outcomes across a range of cardiovascular disorders. Th ey must be frustrated, therefore, by the technique's failure to penetrate clinical practice, conflicting reports of its efficacy and mechanistic uncertainty combining to undermine clinical confidence in the utility of RIPC. Some recent randomised trials have been favorable, reporting protection against contrast-induced nephropathy during cardiac catheterization 65 and reduction in myocardial injury during heart valve surgery 66 . Per haps the most favorable has been a randomized trial of prehospital RIPC in 333 patients with STEMI who underwent primary PCI 67 . Th e group with RIPC showed a significant improvement in myocardial salvage index compared with the group without (0.75 vs 0.55) although the trial was not powered for coronary events. Against this must be set a negative trial of RIPC in a group of patients undergoing CABG 68 , but this is unlikely to be the last word, and already a meta-analysis of nine studies including 704 patients has concluded that RIPC significantly reduces troponin release during CABG 69 . Mechanistic studies of interest include one crossover study in patients with stable coronary artery disease in which RIPC reduced platelet activation during exercise testing without protecting against ischaemic ECG changes 70 . In another study of forearm blood flow using venous plethysmography in healthy volunteers, RIPC protected against impaired endothelium-dependent vasomotor function induced by ischaemia 71 . However, this protection was unaff ected by infusion of a bradykinin B2 receptor antagonist, leading the authors to conclude that bradykinin is not a mediator of RIPC.
PROGNOSTIC BIOMARKERS IN STABLE CAD
Circulating biomarkers. Interest in circulating cardiovascular biomarkers has never been higher, and methodological papers have been developed to alert researchers to the standards necessary for proper evaluation of their prognostic utility 72, 73 . However, a systematic review of 83 CRP studies was critical of their general quality and concluded that 'multiple types of reporting bias, and publication bias, make the magnitude of any independent association between CRP and prognosis among patients with stable coronary disease sufficiently uncertain that no clinical practice recommendations can be made' 74 . Th e same authors were equally critical of 19 BNP studies in patients with stable coronary disease, reporting that clinically useful measures of prediction and discrimination were generally unavailable, and concluding that the unbiased strength of association of BNP with prognosis in stable coronary disease is unclear 75 . Th e availability of high-sensitivity assays has seen renewed interest in troponins as markers of risk in stable coronary disease, a US study of 984 patients in the Heart and Soul Study reporting that each doubling in hs-cTnT level is associated with a 37% higher rate of cardiovascular events 76 . Meanwhile the PEACE investigators have reported that among 3623 patients with stable coronary artery disease, hs-cTNI is independently associated with cardiovascular death or heart failure (HR 1.88 (1.33 to 2.66; p<0.001)), the association with non-fatal myocardial infarction being weaker (1.03 to 2.01; p=0.031) 77 . Evidence from CTCA suggests that clinically silent rupture of non-calcified plaque with subsequent microembolisation is a likely pathophysiological mechanism of troponin elevation 78 but it is too soon to know whether it will have a clini-cal role in the prognostic assessment of stable coronary artery disease. Th e same applies to the mid-regional portion of proadrenomedullin and other biomarkers currently under investigation 79 . Vascular biomarkers. Carotid intima-media thickness (cIMT) is well established as a predictor of cardiovascular events in the general population and, more weakly, in patients with stable coronary artery disease 80 . Its predictive value may be enhanced by additional consideration of the extent of carotid plaque allowing derivation of the 'total burden score' which was shown by Chinese investigators to improve the prediction of the 5-year risk of cardiovascular endpoints compared with cIMT alone 81 . Certainly, the value of cIMT alone for cardiovascular risk prediction in the general population is under question following a large meta-analysis of participant-level data in 45 828 individuals in which cIMT added almost nothing to the Framingham Risk Score 82 . Further questions have been raised by another meta-analysis of participant-level data which included 36 984 individuals followed-up for an average of 7 years 83 . Th e investigators showed no association between progression of cIMT and risk of cardiovascular events, questioning the validity of using changes in cIMT as a surrogate endpoint in trials of cardiovascular risk.
Calcium and parathyroid hormone. Studies suggesting that people who take calcium supplements may be increasing their risk of myocardial infarction 84, 85 have stimulated interest in serum calcium and its relation to cardiovascular events in patients with CHD. A recent study has confirmed that vitamin D, parathyroid hormone and calcium show association with cardiovascular risk factors in US adolescents 86 , and now we have data in 1017 patients with stable coronary artery disease followed-up for a median of 8.1 years, suggesting that high calcium levels, but not high phosphate levels, might be asso-ciated with all-cause and cardiovascular mortality (HR 2.39 to 4.66)) 87 . Th e mechanism of this association is unclear, but the demonstration in the same cohort of a similar association between high parathyroid hormone and cardiovascular mortality may implicate calcium mobilisation from bone on the causal pathway 88 .
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